Prospective Study for the Application of Cytosorb® in Critically Ill Patients (Cyto-SOLVE)

Ludwig Maximilian University of Munich

Status: Completed

Conditions: Rhabdomyolysis; Cytokine Storm; Acute Liver Injury

Treatments: Device: Cytosorb therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT04913298

21-0236

Details and patient eligibility

About

The mortality of critically ill patients is persistently high and requires targeted therapy of pathophysiological disorders. One approach to optimize therapy is the use of the cytokine adsorber Cytosorb®, which has a CE certification for the indications hyperinflammation, rhabdomyolysis and liver failure and is therefore frequently used in patients with sepsis, polytrauma and acute liver failure. Although few clinical data describe the efficiency mostly retrospectively, there are no data on real-time elimination performance and saturation kinetics during the course of treatment. These questions should be answered by the present study.

Enrollment: 57 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• intensive care therapy
• hyperinflammation or acute liver dysfunction or rhabdomyolysis
• need of continuous renal replacement therapy
• treatment with Cytosorb (decision of the attending physician)

Exclusion criteria

• other reasons for Cytosorb application

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

57 participants in 1 patient group

Cytosorb therapy

Other group

Description:

blood samples are taken before and after the cytokine adsorber at given times

Treatment:

Device: Cytosorb therapy